Evidence map›Paper›PMID 27531410›Full record

ArticleVaccine2016

Vaccination program in a resource-limited setting: A case study in the Philippines.

Sarocha Chootipongchaivat, Varit Chantarastapornchit, Wantanee Kulpeng, Joyce Anne Ceria, Niña Isabelle Tolentino, Yot Teerawattananon

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sarocha ChootipongchaivatHealth Intervention and Technology Assessment Program (HITAP), 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Rd., Mueng, Nonthaburi 11000, Thailand. Electronic address: sarocha.c@hitap.net.
Varit ChantarastapornchitHealth Intervention and Technology Assessment Program (HITAP), 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Rd., Mueng, Nonthaburi 11000, Thailand. Electronic address: varitt@gmail.com.
Wantanee KulpengHealth Intervention and Technology Assessment Program (HITAP), 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Rd., Mueng, Nonthaburi 11000, Thailand. Electronic address: wantanee.k@hitap.net.
Joyce Anne CeriaPharmaceutical Division (PD) - Office for Health Regulation (OHR), 3rd Floor, Bldg. 15, Department of Health, San Lazaro Compound, Rizal Avenue, Sta Cruz, 1003 Manila, Philippines. Electronic address: dohncpam@gmail.com.
Niña Isabelle TolentinoPharmaceutical Division (PD) - Office for Health Regulation (OHR), 3rd Floor, Bldg. 15, Department of Health, San Lazaro Compound, Rizal Avenue, Sta Cruz, 1003 Manila, Philippines. Electronic address: nimtolentino@gmail.com.
Yot TeerawattananonHealth Intervention and Technology Assessment Program (HITAP), 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Rd., Mueng, Nonthaburi 11000, Thailand. Electronic address: yot.t@hitap.net.
Ministry of Public Health · THDepartment of Health · PHHealth Intervention and Technology Assessment Program · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveImplementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative implications of human resources for health (HRH) is still lacking. Therefore, this study aims to estimate the HRH impact of introducing pneumococcal conjugate vaccine (PCV) using a model-based economic evaluation.

methodsThis study adapted a Markov model from a prior study that was conducted in the Philippines for assessing the cost-effectiveness of 10-valent and 13-valent PCV compared to no vaccination. The Markov model was used for estimating the number of cases of pneumococcal-related diseases, categorized by policy options. HRH-related parameters were obtained from document reviews and interviews using the quantity, task, and productivity model (QTP model).

resultsThe number of full-time equivalent (FTE) of general practitioners, nurses, and midwives increases significantly if the universal vaccine coverage policy is implemented. A universal coverage of PCV13 - which is considered to be the best value for money compared to other vaccination strategies - requires an additional 380 FTEs for general practitioners, 602 FTEs for nurses, and 205 FTEs for midwives; it can reduce the number of FTEs for medical social workers, paediatricians, infectious disease specialists, neurologists, anaesthesiologists, radiologists, ultrasonologists, medical technologists, radiologic technologists, and pharmacists by 7, 17.9, 9.7, 0.4, 0.1, 0.7, 0.1, 12.3, 2, and 9.7, respectively, when compared to the no vaccination policy.

conclusionThis is the first attempt to estimate the impact of HRH alongside a model-based economic evaluation study, which can be eventually applied to other vaccine studies, especially those which inform resource allocation in developing settings where not only financial resources but also HRH are constrained.

Indexed as

Cost-Benefit AnalysisHumansImmunization ProgramsModels, EconomicPhilippinesPneumococcal InfectionsPneumococcal VaccinesVaccination10-valent pneumococcal conjugate vaccine13-valent pneumococcal vaccinePneumococcal VaccinesHRHHuman resources for healthPCVPhilippinesPneumococcal conjugate vaccineVaccination coverage

Identifiers

PMID27531410
PMCPMC5022401
OpenAlexW2513435566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.